Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIN FE 1.5/30 vs DEMULEN 1/50-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration; alters endometrial receptivity. Norethindrone also decreases ovarian estrogen production.
Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years (if no known contraindications and have achieved menarche),Off-label: Dysmenorrhea, menstrual irregularities, endometriosis-associated pain, hirsutism
FDA: Prevention of pregnancy,Off-label: Treatment of acne vulgaris, dysmenorrhea, endometriosis-related pain, menstrual irregularity
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets.
One tablet orally once daily for 28 consecutive days per cycle.
Ethinyl estradiol terminal half-life is approximately 13-17 hours; norethindrone terminal half-life is approximately 7-10 hours. Steady-state is reached within 5-10 days.
Ethinylestradiol: terminal elimination half-life ~13-27 hours (mean ~17 hours); ethynodiol diacetate (as norethindrone): terminal elimination half-life ~8-11 hours; clinical context: achieved steady-state within 5-10 days; accumulation not significant due to dose interval.
Ethinyl estradiol: primarily CYP3A4 metabolism with first-pass hepatic and intestinal metabolism; undergoes conjugation (glucuronidation and sulfation). Norethindrone: extensively metabolized via reduction, glucuronidation, and sulfation; CYP3A4 also involved.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism with sulfation and glucuronidation. Ethynodiol diacetate: Deacetylated to norethynodrel, then extensively metabolized via reduction and conjugation.
Ethinyl estradiol and norethindrone are primarily excreted via renal (urine) and fecal routes. Approximately 40-50% of ethinyl estradiol is excreted renally as metabolites, with 20-30% in feces. Norethindrone metabolites are excreted ~50-70% renally and 20-30% fecally. Less than 5% is excreted unchanged.
Ethinylestradiol and ethynodiol diacetate are extensively metabolized; urinary excretion accounts for ~40% of ethinylestradiol metabolites and ~50-60% of ethynodiol diacetate metabolites; fecal excretion accounts for ~30% of ethinylestradiol metabolites and ~35% of ethynodiol diacetate metabolites; biliary excretion contributes to enterohepatic circulation.
Ethinyl estradiol: ~97-98% bound, primarily to albumin (70%) and sex hormone-binding globulin (SHBG). Norethindrone: ~61-63% bound, primarily to albumin and SHBG.
Ethinylestradiol: >97% bound, primarily to albumin, with ~2% bound to sex hormone-binding globulin (SHBG); ethynodiol diacetate (as norethindrone): ~95% bound, primarily to albumin and SHBG.
Ethinyl estradiol: Vd approximately 2.5-4 L/kg; norethindrone: Vd approximately 4-5 L/kg. Distribution into breast milk and body fat is notable.
Ethinylestradiol: Vd ~2-4 L/kg; distributes extensively into body tissues; ethynodiol diacetate (as norethindrone): Vd ~4 L/kg; indicates wide distribution including reproductive tissues.
Ethinyl estradiol: ~40-50% due to first-pass metabolism; norethindrone: ~50-65% with first-pass metabolism. Food may increase bioavailability.
Oral: ethinylestradiol bioavailability ~40-60% due to first-pass metabolism; ethynodiol diacetate bioavailability ~60-80% after oral administration.
Contraindicated in patients with renal impairment or renal disease.
No dosage adjustment required for renal impairment. Use is not recommended in patients with severe renal impairment due to potential adverse effects.
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). Use with caution in Child-Pugh class A, consider alternative therapy.
Contraindicated in patients with Child-Pugh C cirrhosis. For Child-Pugh A or B, use is generally not recommended; if used, monitor closely for adverse effects.
Not indicated for use in pediatric females before menarche. For postmenarchal pediatric patients, dosage same as adults: one tablet orally once daily for 21 days, then 7 placebo tablets.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 28 days per cycle.
Not indicated for use in postmenopausal women. Safety and efficacy not established in geriatric population.
Not indicated for use in postmenopausal women. No specific dose adjustment recommended for elderly, but consider increased risk of thromboembolic disorders.
Cigarette smoking increases risk of serious cardiovascular events (stroke, myocardial infarction, thromboembolism) from combined oral contraceptives. Risk increases with age and number of cigarettes smoked, particularly in women >35 years. Advise not to smoke.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism). Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction, especially in smokers >35 years, hypertension, obesity, diabetes, hyperlipidemia, or migraine with aura. Monitor for undiagnosed abnormal genital bleeding, liver disease, hypertension, depression, migraine, carbohydrate/lipid effects, hereditary angioedema, chloasma, retinal thrombosis, gallbladder disease, and anaphylactic reactions. Discontinue if jaundice, vision changes, or severe headache occurs.
Thromboembolic disorders (DVT, PE, stroke, MI),Hepatic neoplasia (benign/malignant liver tumors),Increased risk of gallbladder disease,Hypertension,Carbohydrate/lipid metabolic effects,Ocular disturbances (retinal thrombosis, optic neuritis),Depression,Fetal harm if used during pregnancy
Current or history of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction, or transient ischemic attack; known coagulation disorders; valvular heart disease with complications; uncontrolled hypertension; diabetes with vascular involvement; headache with focal neurological symptoms (migraine with aura) in women >35; estrogen-sensitive cancer (e.g., breast cancer); hepatic tumors or active liver disease; undiagnosed abnormal uterine bleeding; pregnancy; hypersensitivity to components; cigarette smoking in women >35 years; use with hepatitis C drug regimens containing ombitasvir/paritaprevir/ritonavir (with or without dasabuvir).
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Grapefruit or grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects; avoid concurrent consumption. No specific dietary restrictions otherwise. Iron supplement in active tablets may cause GI upset; take with food to reduce irritation.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinical significance is unclear. Maintain consistent intake of vitamin C-rich foods as they may increase estrogen absorption. Avoid St. John's wort, which reduces contraceptive efficacy.
No increased risk of birth defects observed with oral contraceptives; avoid use in pregnancy due to potential for fetal harm and lack of necessity. First trimester: no consistent evidence of malformations. Second/third trimester: may cause fetal harm from estrogenic effects; discontinue if pregnancy occurs.
Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimesters: association with masculinization of female fetus, adrenal suppression, and possible long-term metabolic effects. Estrogen component may increase risk of VACTERL anomalies.
Small amounts of ethinyl estradiol and norethindrone pass into breast milk; M/P ratio not established. May reduce milk quantity and quality. Not recommended for breastfeeding mothers until weaning complete to avoid infant exposure to sex hormones.
Contraindicated during breastfeeding. Estrogens reduce milk production and quality. M/P ratio not established; ethinyl estradiol and norgestrel are excreted in breast milk in small amounts, potentially causing adverse effects in the infant.
Contraindicated in pregnancy; no dose adjustment applicable. Pharmacokinetic changes in pregnancy (increased clearance) may reduce efficacy if used inadvertently; use alternative contraception.
No adjustments; absolute contraindication in pregnancy. Drug should be discontinued immediately upon pregnancy diagnosis. No established safe dose in pregnancy.
Contains norethindrone 1.5 mg and ethinyl estradiol 30 mcg; low estrogen dose, suitable for women with estrogen sensitivity; iron supplement (ferrous fumarate 75 mg) in last 7 tablets helps prevent iron deficiency; missed pill protocol: if one tablet missed, take as soon as remembered; if two missed in week 1 or 2, take two the next day and two the day after; if two missed in week 3 or three or more missed at any time, discard pack and start new pack next day, use backup contraception for 7 days.
Demulen 1/50-28 is a monophasic combined oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Due to the 50 mcg estrogen dose, it carries an increased risk of venous thromboembolism compared to lower-dose pills; avoid in patients with migraine with aura, hypertension >160/100 mm Hg, or age >35 who smoke. The 28-day pack includes 21 active pills and 7 placebo pills; breakthrough bleeding is more common with higher estrogen. Caution with hepatic enzyme inducers like rifampin or anticonvulsants may reduce efficacy.
Take one tablet daily at the same time, preferably after an evening meal to reduce nausea.,The last 7 tablets (brown) contain iron; do not skip them even if bleeding occurs.,If you miss a pill, refer to the missed pill instructions in the package insert.,Use backup contraception (e.g., condoms) if pills are missed or if you start a new pack late.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first 3 months.,Report severe abdominal pain, chest pain, shortness of breath, severe headache, or vision changes immediately.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,This medication does not protect against sexually transmitted infections (STIs).
Take one pill daily at the same time, preferably with food to reduce nausea.,The first 7 days of the first cycle require a backup contraceptive method if not starting on day 1 of menses.,Missed pill: if one active pill is missed, take it as soon as remembered and continue; if two or more active pills are missed, take the last missed pill, skip the others, use backup for 7 days, and consider emergency contraception.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,Report symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,The 7 placebo pills are for withdrawal bleeding; start next pack on time regardless of bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIN FE 1.5/30 vs DEMULEN 1/50-28, answered by our medical review team.
LARIN FE 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration; alters endometrial receptivity. Norethindrone also decreases ovarian estrogen production.. DEMULEN 1/50-28 is a Combination Oral Contraceptive that works by Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIN FE 1.5/30 and DEMULEN 1/50-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIN FE 1.5/30 is: One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets.. The standard adult dose of DEMULEN 1/50-28 is: One tablet orally once daily for 28 consecutive days per cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIN FE 1.5/30 and DEMULEN 1/50-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIN FE 1.5/30 is classified as Category C. No increased risk of birth defects observed with oral contraceptives; avoid use in pregnancy due to potential for fetal harm and lack of necessity. First trimester: no consistent e. DEMULEN 1/50-28 is classified as Category C. Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.